5
Participants
Start Date
August 31, 2009
Primary Completion Date
August 31, 2011
Study Completion Date
September 30, 2011
ixabepilone
This intravenous treatment will be performed on an outpatient basis. Ixabepilone (15 - 20mg/m2) will be given weekly for 3 weeks, then one week off, every 28 days (4 weeks). The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
lapatinib ditosylate
Lapatinib (1000-1500 mg) will be administered orally on a daily basis. The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
University of California Davis Cancer Center, Sacramento
City of Hope Comprehensive Cancer Center, Duarte
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles
Feist-Weiller Cancer Center at Louisiana State University Health Sciences, Shreveport
Collaborators (2)
National Cancer Institute (NCI)
NIH
Genentech, Inc.
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
University of California, Davis
OTHER